Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.7%

2 terminated out of 54 trials

Success Rate

94.9%

+8.4% vs benchmark

Late-Stage Pipeline

15%

8 trials in Phase 3/4

Results Transparency

22%

8 of 37 completed with results

Key Signals

8 with results95% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (14)
P 1 (2)
P 2 (3)
P 3 (5)
P 4 (3)

Trial Status

Completed37
Recruiting7
Not Yet Recruiting3
Terminated2
Unknown2
Enrolling By Invitation2

Trial Success Rate

94.9%

Benchmark: 86.5%

Based on 37 completed trials

Clinical Trials (54)

Showing 20 of 20 trials
NCT07572890Phase 2Not Yet Recruiting

Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

NCT05092347Phase 1RecruitingPrimary

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT06383390Phase 3Active Not Recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT05106387RecruitingPrimary

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

NCT07391904Not ApplicableEnrolling By InvitationPrimary

Patient-centered Precision Medicine Lab Result Communication for Older Adults

NCT07493642Not ApplicableRecruitingPrimary

Multimedia Health Education on Physical Fitness and Physical Activity for Patients With Chronic Kidney Disease

NCT07381101CompletedPrimary

Trazodone and the Risk of Serious Adverse Events

NCT06202235RecruitingPrimary

Multifrequency MRE in Evaluation of Chronic Kidney Diseases

NCT07399795CompletedPrimary

Citalopram and the Risk of Serious Adverse Events

NCT07387120CompletedPrimary

Sertraline and the Risk of Serious Adverse Events

NCT07382960Completed

Pramipexole and the Risk of Serious Adverse Events

NCT07274241CompletedPrimary

Escitalopram and the Risk of Serious Adverse Events

NCT07274228CompletedPrimary

Tamsulosin and the Risk of Serious Adverse Events

NCT07193056Not Yet Recruiting

The CPH-MBD Cohort

NCT06589791Completed

A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists

NCT04064827Phase 3TerminatedPrimary

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT02119832Not ApplicableCompletedPrimary

A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)

NCT02119845Not ApplicableCompletedPrimary

A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-001

NCT06203704CompletedPrimary

Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients

NCT07179978CompletedPrimary

Lorazepam and the Risk of Serious Adverse Events

Scroll to load more

Research Network

Activity Timeline